Fleury SA
BOVESPA:FLRY3
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Valuation Scenarios
If EV/OCF returns to its 3-Year Average (5.8), the stock would be worth R$17.52 (7% upside from current price).
| Scenario | EV/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 5.4 | R$16.32 |
0%
|
| 3-Year Average | 5.8 | R$17.52 |
+7%
|
| 5-Year Average | 7.3 | R$22.33 |
+37%
|
| Industry Average | 5 | R$15.1 |
-7%
|
| Country Average | 8.9 | R$26.99 |
+65%
|
Forward EV/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | EV/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| BR |
|
Fleury SA
BOVESPA:FLRY3
|
8.9B BRL | 5.4 | 14.5 | |
| US |
|
CVS Health Corp
NYSE:CVS
|
100.2B USD | 14.1 | 56.7 | |
| US |
C
|
Cigna Group
XMUN:CGN
|
68.5B EUR | 10.5 | 13.2 | |
| US |
|
Cigna Corp
NYSE:CI
|
73.7B USD | 0 | 12.4 | |
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
23.1B EUR | 11.1 | 23.6 | |
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
22.9B EUR | 12.2 | 17.9 | |
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
22.1B USD | 14.5 | 21.7 | |
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
21.8B USD | 16 | 24.8 | |
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
10.9B EUR | 6.5 | 11.1 | |
| US |
|
Guardant Health Inc
NASDAQ:GH
|
11.5B USD | -64.9 | -27.6 | |
| US |
|
DaVita Inc
NYSE:DVA
|
10.6B USD | 10.5 | 14.2 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 5.8 |
| Median | 8.9 |
| 70th Percentile | 12.8 |
| Max | 3 401.7 |
Other Multiples
Fleury SA
Glance View
Fleury SA, originally founded in 1926, stands as a paragon of healthcare excellence in Brazil, evolving over nearly a century into a leading provider of medical diagnostics and integrated healthcare services. Driven by a culture of innovation and customer commitment, the company operates a network of strategically located diagnostic centers, offering a comprehensive array of tests, from basic blood work to sophisticated imaging. At the core of Fleury's operations is their ability to seamlessly blend cutting-edge technology with medical expertise, enabling them to deliver accurate diagnostics and personalized healthcare solutions. This approach not only enhances patient experiences but also fortifies their position in a highly competitive marketplace. In generating revenue, Fleury SA capitalizes on its robust infrastructure and premium service quality. The company’s business model thrives on a vast portfolio of diagnostic services, catering to an array of clientele — from individuals seeking routine checks to physicians requiring specialized analyses. Additionally, Fleury extends its reach through partnerships with hospitals and clinics, further solidifying its reputation and reliability. By maintaining a focus on operational efficiency and strategic expansions, the company ensures steady cash flows, which in turn are reinvested into technological advancements and service enhancements. This, coupled with their focus on high-quality client relations, fuels Fleury’s ability to retain a loyal customer base and sustain its financial growth trajectory.